Key points are not available for this paper at this time.
MTA and iRoot BP Plus demonstrated superior clinical and radiographic success, with Biodentine as a strong alternative. Although CH showed lower success rates, its long history of use supports its continued relevance. These findings should be interpreted cautiously due to study heterogeneity, the limited number of high-quality trials, and short follow-up in some cases. Further well-designed randomized controlled trials with long-term follow-up are needed to confirm these results and guide material selection for pulpotomy in permanent teeth.
Widyasari et al. (Wed,) studied this question.